PJP - Invesco Dynamic Pharmaceuticals ETF
| Previous Close | 60.79 |
| Open | 60.67 |
| Bid | 59.21 x 800 |
| Ask | 62.50 x 800 |
| Day's Range | 60.20 - 61.00 |
| 52 Week Range | 58.29 - 74.29 |
| Volume | 22,552 |
| Avg. Volume | 26,900 |
| Net Assets | 416.59M |
| NAV | 60.39 |
| PE Ratio (TTM) | N/A |
| Yield | 1.12% |
| YTD Return | -1.03% |
| Beta (3Y Monthly) | 1.10 |
| Expense Ratio (net) | 0.57% |
| Inception Date | 2005-06-23 |
- ETF Trends•9 days ago
Legal Troubles Beset Pharmaceutical Sector ETFs
Pharmaceutical ETFs may be in trouble with legal troubles looming over the industry. The drugmaker segment recently sold-off after an amended civil antitrust complaint brought by more than 40 state attorneys ...
- Zacks•14 days ago
Pharma ETFs Down Despite Solid Q1 Results
Despite such robust results, pharma ETFs have been trending downward in a month.
- ETF Trends•last month
4 ETFs to Consider with Big Pharma on the Senate’s Hot Seat
Big pharmaceutical companies were on the hot seat at Capitol Hill today with CVS Health, Cigna, Prime Therapeutics, Humana, and UnitedHealthcare's OptumRx testifying before the Senate Finance Committee on the rising cost of prescription drugs. Among the topics discussed included rebates paid by drug makers contributing to the high costs and the drug industry's pursuit of profits--all to shift the blame from the pharmaceutical companies to the drug makers. U.S. President Donald Trump has already lambasted the pharmaceutical industry for the rising costs associated with prescription drugs.
- Zacks•2 months ago
4 Sector ETFs That Crushed S&P 500 in Decade-Old Bull Run
These sector ETFs emerged winners in the 10-year old bull market.
- Zacks•3 months ago
Why These Pharma ETFs Rallied on Thursday
A few pharma ETFs hit a one-month high on Feb 28. Why?
- ETF Trends•3 months ago
Pharmaceutical ETFs Break Out on Horizon Pharma’s Positive Drug Results
Pharmaceutical sector-related ETFs stood out Thursday after Horizon Pharma (HZNP) revealed positive test results for its treatment of thyroid eye disease, or TED. Among the better performing non-leveraged ETFs of Thursday, the First Trust Nasdaq Pharmaceuticals ETF (FTXH) rose 1.8%, Invesco Dynamic Pharmaceuticals ETF (PJP) gained 1.5% and SPDR Pharmaceuticals ETF (XPH) increased 2.3%. Horizon Pharma shares surged 32.5% Thursday following the release of positive test results in its Phase 3 trial of its thyroid eye disease drug, teprotumumab, TheStreet reports.
- Zacks•3 months ago
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
- Zacks•3 months ago
A Look at Pharma ETFs Post Q4 Results
The strong results but downbeat guidance led to decent returns in the pharma ETFs over the past month.
- Zacks•5 months ago
Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus
The news has put the spotlight on a number of healthcare ETFs, especially biotech and pharma, which could be the best ways for investors to tap the opportunity arising from the BMY-CELG deal.
Market Realist•6 months agoHow Bausch Health’s Financials Look in November
Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017, a ~4% YoY decline. Bausch Health generated revenues of $6.26 billion over the first nine months of this year compared to $6.56 billion in the same period the prior year, reflecting a ~5% YoY decline.
- Zacks•7 months ago
ETF Strategies for the Midterm Elections
Investors should focus on some strategies as to which sector should they take positions or which should be avoided if bipartisan government forms.
- 7 months ago
ETF Plays for a Divided Midterm Elections
With a contentious midterms election season coming up, many anticipate a split government that could potentially impact the way ETF investors ride the markets ahead. Some expectations point to Democrats winning back the House of Representatives and the Republicans maintaining a narrow hold on the Senate - Republicans currently dominate both chambers. "If the consensus expectation of a divided government turns out to be correct, the most likely political consequences would be an increase in investigations and uncertainty surrounding fiscal deadlines," David Kostin, Goldman's chief U.S. equity strategist, said in a note.
Market Realist•7 months agoA Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.
- Investopedia•7 months ago
Top 5 Pharmaceutical ETFs for 2018
The healthcare sector will continue to see political attention in the remainder of 2018, with the 2017 U.S. tax reform bill influencing it in a number of ways. Its repeal of mandated healthcare is likely to change demand and effect provider participation.
- Market Realist•8 months ago
How Did Pharmaceutical ETFs Perform in Q3 2018?
In this article, we’ll discuss several major ETFs in the pharmaceuticals sector and their third-quarter returns. The chart below compares the market capitalization of these pharmaceutical ETFs on October 3.
- Market Realist•8 months ago
What’s Eli Lilly’s Valuation as of September 27?
Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue compared to $5.8 billion in the second quarter of 2017.
- Market Realist•8 months ago
Allergan’s SpotLyte and Lumivive System
On September 12, Allergan (AGN) announced the launch of SpotLyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. On September 6, Allergan announced the launch of its dual-acting product, the SkinMedica Lumivive System. SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.
Market Realist•8 months agoSUPN’s Product Portfolio and Financial Guidance
Supernus Pharmaceuticals’ (SUPN) Trokendi XR generated revenues of $76.4 million in the second quarter, compared to $56.0 million in the second quarter of 2017, reflecting ~36.4% YoY (year-over-year) growth.
- ETF Trends•9 months ago
Pharmaceutical ETFs Could Maintain Their Momentum
Pharmaceutical stocks and sector-related exchange traded funds have enjoyed a great summer and the rally may continue to have legs. Meanwhile, the broader iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) rose 10.6%. There were no clear catalysts to explain the rally as we did not witness any memorable earnings beats, new clinical trials or large-scale deals, the Wall Street Journal reports.
- Simply Wall St.•9 months ago
Is Projprzem SA’s (WSE:PJP) Balance Sheet Strong Enough To Weather A Storm?
Investors are always looking for growth in small-cap stocks like Projprzem SA (WSE:PJP), with a market cap of zł115.47m. However, an important fact which most ignore is: how financially healthyRead More...
- Market Realist•9 months ago
Examining Pfizer’s Performance by Geography in Q2 2018
Pfizer (PFE) reported a rise in revenue in international markets during the second quarter. The Innovative Health segment reported a rise of 3% in revenue to ~$4.58 billion, while the Essential Health segment reported a ~14% fall in revenue to $1.65 billion. The rise in the Innovative Health segment was driven by a 5% rise in vaccines sales, a 5% rise in oncology sales, a 33% rise in inflammation and immunology sales, and a 1% rise in consumer healthcare sales.
